Blocking Key Enzyme Minimizes Stroke Injury
Source Newsroom: UT Southwestern Medical Center
Newswise — DALLAS – June 26, 2014 – A drug that blocks the action of the enzyme Cdk5 could substantially reduce brain damage if administered shortly after a stroke, UT Southwestern Medical Center research suggests.
The findings, reported in the June 11 issue of the Journal of Neuroscience, determined in rodent models that aberrant Cdk5 activity causes nerve cell death during stroke.
“If you inhibit Cdk5, then the vast majority of brain tissue stays alive without oxygen for up to one hour,” said Dr. James Bibb, Associate Professor of Neurology and Neurotherapeutics at UT Southwestern and senior author of the study. “This result tells us that Cdk5 is a central player in nerve cell death.”
More importantly, development of a Cdk5 inhibitor as an acute neuroprotective therapy has the potential to reduce stroke injury.
“If we could block Cdk5 in patients who have just suffered a stroke, we may be able to reduce the number of patients in our hospitals who become disabled or die from stroke. Doing so would have a major impact on health care,” Dr. Bibb said.
While several pharmaceutical companies worked to develop Cdk5 inhibitors years ago, these efforts were largely abandoned since research indicated blocking Cdk5 long-term could have detrimental effects. At the time, many scientists thought aberrant Cdk5 activity played a major role in the development of Alzheimer’s disease and that Cdk5 inhibition might be beneficial as a treatment.
Based on Dr. Bibb’s research and that of others, Cdk5 has both good and bad effects. When working normally, Cdk5 adds phosphates to other proteins that are important to healthy brain function. On the flip side, researchers have found that aberrant Cdk5 activity contributes to nerve cell death following brain injury and can lead to cancer.
“Cdk5 regulates communication between nerve cells and is essential for proper brain function. Therefore, blocking Cdk5 long-term may not be beneficial,” Dr. Bibb said. “Until now, the connection between Cdk5 and stroke injury was unknown, as was the potential benefit of acute Cdk5 inhibition as a therapy.”
In this study, researchers administered a Cdk5 inhibitor directly into dissected brain slices after adult rodents suffered a stroke, in addition to measuring the post-stroke effects in Cdk5 knockout mice.
“We are not yet at a point where this new treatment can be given for stroke. Nevertheless, this research brings us a step closer to developing the right kinds of drugs,” Dr. Bibb said. “We first need to know what mechanisms underlie the disease before targeted treatments can be developed that will be effective. As no Cdk5 blocker exists that works in a pill form, the next step will be to develop a systemic drug that could be used to confirm the study’s results and lead to a clinical trial at later stages.”
Currently, there is only one FDA-approved drug for acute treatment of stroke, the clot-busting drug tPA. Other treatment options include neurosurgical procedures to help minimize brain damage.
Additional UT Southwestern scientists from the Department of Psychiatry who contributed to this study were lead author and former postdoctoral researcher Dr. Douglas Meyer; postdoctoral researcher Dr. Melissa Torres-Altoro; Instructor Dr. Florian Plattner; and former postdoctoral researcher Dr. Janice Kansy.
The work was supported by grants from the National Institutes of Health. Pharmaceutical company Boehringer Ingelheim provided the Cdk5-inhibiting compound indolinone used in the study.
This work is just one of numerous cutting-edge stroke research studies taking place at UT Southwestern, where patients have access to the newest treatments and clinical trials due in part to the stroke center’s recent Advanced Comprehensive Stroke Center certification. This designation is the highest level of certification for stroke care by The Joint Commission. UT Southwestern’s Robert D. Rogers Advanced Comprehensive Stroke Center offers the most advanced treatment available from a multidisciplinary team of vascular neurologists, endovascular specialists, vascular surgeons, neuro-radiologists and neuro-intensivists who are on call 24 hours a day to treat stroke patients.
About UT Southwestern Medical Center
UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty includes many distinguished members, including six who have been awarded Nobel Prizes since 1985. Numbering more than 2,700, the faculty is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide medical care in 40 specialties to nearly 91,000 hospitalized patients and oversee more than 2 million outpatient visits a year.
This news release is available on our home page at
To automatically receive news releases from UT Southwestern via email,
subscribe at www.utsouthwestern.edu/receivenews